In a similar study, venetoclax combined with the FLT3 inhibitor quizartinib showed synergistic anti-leukaemic activity in cell lines and primary patient samples, and prolonged the survival of FLT-ITD+ AML mice, compared to the modest effects of single-agent treatments (119). Here, FLT1 is linked to acute myeloid leukemia.